VTGN

VistaGen Therapeutics earns a Neutral rating, with a low-40s composite score and conviction at two out of five. Regulatory is the strongest pillar, scoring just below 50, supported by an 80 enforcement subscore, no recorded enforcement hits, and a midrange domestic jurisdiction posture. Fundamentals follow in the mid-40s, where strong revenue growth and gross margin performance are offset by severe operating losses, limited scale, and a stretched financial condition. Market contributes 40 because no institutional quote is available, while editorial ranks last at 30 amid no qualifying CIN newsroom coverage or briefs. The pillar mix supports balance rather than directional conviction.

Licensed fundamentals data show year-over-year revenue growth of nearly 30% and a full gross margin, producing subscores near 80 and 100, respectively. Those strengths do not translate into operating leverage: the operating margin was negative at almost 36 times revenue, EBITDA was a loss of roughly $72 million, and the cash-burn ratio approached 6.8. Market capitalization was approximately $10.6 million, leaving the scale subscore near the floor, while the cash-runway subscore remained only 15. Reported net income was flat, but that figure does not override the negative EBITDA profile or the stated stretched condition. Primary regulatory filings show no dated latest filing and no recorded events across either the 90-day or 180-day windows, limiting cadence to a 25 subscore. Institutional pricing feeds provide no current quote, and CIN newsroom coverage contains no qualifying activity.

The clearest upside catalyst sits within the regulatory pillar, already the company’s strongest contributor. A new dated primary regulatory filing could restore observable cadence, improve the weakest component inside that pillar, and provide a concrete event for institutional pricing feeds and CIN newsroom coverage to absorb. With enforcement scoring already strong, incremental rating support depends less on compliance cleanup than on visible, timely regulatory activity that confirms corporate progress. The single most important signal to watch is the appearance of a current primary regulatory filing that re-establishes filing cadence.